APA (7th ed.) Citation

M, C., S, J., L, Y., CA, G., M, K., D, T., . . . SM, S. (2021). A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiology of disease, 159, 105507. https://doi.org/10.1016/j.nbd.2021.105507

Chicago Style (17th ed.) Citation

M, Cosden, et al. "A Novel Glucosylceramide Synthase Inhibitor Attenuates Alpha Synuclein Pathology and Lysosomal Dysfunction in Preclinical Models of Synucleinopathy." Neurobiology of Disease 159 (2021): 105507. https://doi.org/10.1016/j.nbd.2021.105507.

MLA (9th ed.) Citation

M, Cosden, et al. "A Novel Glucosylceramide Synthase Inhibitor Attenuates Alpha Synuclein Pathology and Lysosomal Dysfunction in Preclinical Models of Synucleinopathy." Neurobiology of Disease, vol. 159, 2021, p. 105507, https://doi.org/10.1016/j.nbd.2021.105507.